Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada. Show more
Location: The Canadian Venture Building, Toronto, ON, M5C 1P1, Canada | Website: https://revivethera.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
6.118M
52 Wk Range
$0.01 - $0.03
Previous Close
$0.01
Open
$0.02
Volume
15,501
Day Range
$0.01 - $0.02
Enterprise Value
6.088M
Cash
46.42K
Avg Qtr Burn
-259.5K
Insider Ownership
1.51%
Institutional Own.
0.00%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bucillamine Details COVID-19 | Phase 3 Update |